Articles

NanoSpot.ai’s agreement with the Greek company Opto enables the commercialization and distribution in Europe of NanoSpot.ai’s line of antibody tests, including the SARS-CoV-2 test pictured here.

ARUP Consult^®, a free source of laboratory testing information for clinicians, released several new and updated resources in August.

These images depict the distinct genetic profiles found in patients with pathogenic germline DDX41 variants and variants of unknown significance (VUSs).

Patricia Slev, PhD, section chief of Immunology at ARUP Laboratories, coauthored a newly published study that looked at COVID-19-related risks facing emergency department workers early in the pandemic.

ARUP’s new autonomous intelligent vehicle (AIV) helps its coworkers in the lab by transporting specimens to storage, freeing up staff to focus on other tasks. Here, a team member unloads samples delivered by the AIV.

ARUP Laboratories is eighth in Utah on Forbes magazine’s list of America’s Best Employers By State, a testament to the good working environment ARUP maintains for all its employees, including for these specialists in the company’s Automated Core Lab.

Students practice pipetting skills during the first laboratory medicine summer camp held by the Division of Medical Laboratory Sciences in the Department of Pathology at University of Utah Health.

Photo credit: Adriana Callahan

Kidneys perform critical functions within the body, and kidney impairment can lead to severe health consequences. ARUP’s adoption of a new equation to assess kidney function will enable better recognition and diagnosis of kidney disease in populations adversely affected by use of a previous equation.

Sandy Richman, MBA, C(ASCP), director of ARUP Healthcare Advisory Services, is among ARUP experts who contributed to a newly published article in Academic Pathology that adds to the understanding of what constitutes a successful laboratory stewardship program.

Tracy George, MD, ARUP president and chief scientific officer (left); Jonathan Genzen, MD, PhD, chief medical officer (center); and Jenna Rychert, PhD, medical director of operational informatics and microbial immunology (right), authored a letter to the editor of JAMA that was published on August 2, 2022.